This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
5/13/2026
Ann O’Reilly
Head of Investor Relations & MC
Thank you very much for joining FY2025Q4 Learning School for Takeda Pharmaceutical Company. An O'Reilly IR head, I will serve as MC.
Conference Moderator
IR Team / Language Moderator
First, language setting.
Ann O’Reilly
Head of Investor Relations & MC
For those of you who wish to listen to this call in English, please select English in the Zoom language select button. Before starting, I'd like to remind everyone that we will be discussing forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results made different materially from those discussed today. The factors that could cause actual results to differ materially are discussed in our most recent Form 20F and in our other SEC findings.
You're reading a preview of the TAK Q4 2025 earnings call.
Free account.
Disclaimer